Liver Biopsies in a Mouse Model of NASH
Diet-induced mouse models are commonly used for preclinical modeling of nonalcoholic steatohepatitis (NASH) but can present challenges due to inter-animal variability in phenotype development. To better measure therapeutic efficacy, researchers need a method to assess baseline disease phenotype prior to the start of their study.
Determining Baseline Disease Phenotype in Mouse Models of NASH
Stephanie Oldham, Associate Scientist at AstraZeneca, and Christian Rivera, Research Animal Technician at AstraZeneca, will share how they have successfully used survivable liver biopsies to determine baseline disease phenotype, including the level of liver fibrosis for individual animals. This information enables the exclusion of unsuitable animals from experiments and allows for better randomization of animals into study groups.
Download this on-demand webinar to learn:
- Why in vivo baseline liver biopsies are important for translational purpose
- Explore the effects of therapeutics by examining levels of disease before and after intervention
- Discover how to perform a liver biopsy in a mouse model of NASH
Stephanie Oldham
Associate Scientist | AstraZeneca
Stephanie Oldham is an Associate Scientist at AstraZeneca in Gaithersburg, MD, USA. She studies the pharmacology of metabolic diseases within the Cardiovascular, Renal, & Metabolism (CVRM) BioPharmaceuticals R&D Department.
Christian Rivera
Research Animal Technician in the Animal Sciences and Technologies Group | AstraZeneca
Christian Rivera is a Research Animal Technician in the Animal Sciences and Technologies Group at AstraZeneca in Gaithersburg, MD, USA. He performs in vivo studies with the Cardiovascular, Renal, & Metabolism (CVRM) BioPharmaceuticals R&D Department.